The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor
... the ORs hovered close to one for all outcomes except for fatal myocardial infarction, where a trend toward benefit was noted. This suggests that hypertension control and not the development of newonset diabetes drives these end points over the study time period. It may be that longer-term follow-up ...
... the ORs hovered close to one for all outcomes except for fatal myocardial infarction, where a trend toward benefit was noted. This suggests that hypertension control and not the development of newonset diabetes drives these end points over the study time period. It may be that longer-term follow-up ...
Ovarian Cancer Findings Support Metformin
... to a "growing body of evidence" from epidemiologic and preclinical studies indicating that metformin has antitumor effects. "There is also a biologically plausible mechanism mediating metformin's protective effect in cancer through AMPK (adenosine monophosphate-activated protein kinase) activation a ...
... to a "growing body of evidence" from epidemiologic and preclinical studies indicating that metformin has antitumor effects. "There is also a biologically plausible mechanism mediating metformin's protective effect in cancer through AMPK (adenosine monophosphate-activated protein kinase) activation a ...
Oestrogen replacement therapy and diabetes
... + consider individual clinical profiles : long-standing diabetes with CV risk factors and/or severe microvascular complications ...
... + consider individual clinical profiles : long-standing diabetes with CV risk factors and/or severe microvascular complications ...
PPT - Strong Heart Study
... Recent trials provide greater rationale for lower target LDL-C levels and more intensive LDL-lowering therapy Key modifications to ATP III treatment algorithm for LDL-C: – LDL-C goal <70 mg/dL is therapeutic option for patients at very high risk – Addition of fibrate or nicotinic acid should be cons ...
... Recent trials provide greater rationale for lower target LDL-C levels and more intensive LDL-lowering therapy Key modifications to ATP III treatment algorithm for LDL-C: – LDL-C goal <70 mg/dL is therapeutic option for patients at very high risk – Addition of fibrate or nicotinic acid should be cons ...
skeletal fragility and fracture risk in patients with diabetes
... fractures appear to be increased as well • TZDs appear to increase the risk for hip and other fractures further, especially in postmenopausal women, more risk with longer treatment • Canagliflozin slightly increases the risk of upper and lower limb fractures in older, higher-risk subjects. The incre ...
... fractures appear to be increased as well • TZDs appear to increase the risk for hip and other fractures further, especially in postmenopausal women, more risk with longer treatment • Canagliflozin slightly increases the risk of upper and lower limb fractures in older, higher-risk subjects. The incre ...
Pattern of Dyslipidemia in Pre-diabetes and Diabetes
... suppress hepatic glucose production and to stimulate skeletal muscle glucose uptake.9 The increased flux of FFAs, glucose and insulin into liver can induce overproduction of triglyceriderich VLDL (“large VLDL”) particles. This obvious rise in triglyceride levels as insulin resistance worsens may be ...
... suppress hepatic glucose production and to stimulate skeletal muscle glucose uptake.9 The increased flux of FFAs, glucose and insulin into liver can induce overproduction of triglyceriderich VLDL (“large VLDL”) particles. This obvious rise in triglyceride levels as insulin resistance worsens may be ...
1 - Mayo Clinic
... Northwestern Type 2 Diabetes Mellitus (T2DM) Phenotype: Case and Control Selection from the NUgene Population Introduction The cases and controls have been defined to avoid confounding by inclusion of cases with type 1 diabetes and, as much as possible, of controls at risk for type 2 diabetes which ...
... Northwestern Type 2 Diabetes Mellitus (T2DM) Phenotype: Case and Control Selection from the NUgene Population Introduction The cases and controls have been defined to avoid confounding by inclusion of cases with type 1 diabetes and, as much as possible, of controls at risk for type 2 diabetes which ...
Type 2 Diabetes Mellitus and Lipid Abnormalities
... currently available medicines it is still impossible to have better control of the increased risk of vascular diseases due to type 2 diabetes mellitus. Impaired function of endothelium is an early indicator of cardiovascular disease. A normal endothelium is defined as blood flow response to a vasodi ...
... currently available medicines it is still impossible to have better control of the increased risk of vascular diseases due to type 2 diabetes mellitus. Impaired function of endothelium is an early indicator of cardiovascular disease. A normal endothelium is defined as blood flow response to a vasodi ...
Why are BP control rates poor in type 2 diabetes?
... • Current evidence suggests that in the management of patients with type 2 diabetes mellitus achieving target BP <= 130/80 may be the most important therapeutic goal • Internationally, there is very poor compliance with BP targets in diabetics - partly due to genuine difficulty achieving the BP targ ...
... • Current evidence suggests that in the management of patients with type 2 diabetes mellitus achieving target BP <= 130/80 may be the most important therapeutic goal • Internationally, there is very poor compliance with BP targets in diabetics - partly due to genuine difficulty achieving the BP targ ...
Predicting 6-Year Mortality Risk in Patients With
... less heart failure, and were more likely to have newly diagnosed diabetes compared with patients taking the other drugs. Patients taking TZDs were the most likely to be using insulin, whereas patients taking MEGs had the lowest levels of LDL cholesterol and triglycerides. Cumulative mortality by dru ...
... less heart failure, and were more likely to have newly diagnosed diabetes compared with patients taking the other drugs. Patients taking TZDs were the most likely to be using insulin, whereas patients taking MEGs had the lowest levels of LDL cholesterol and triglycerides. Cumulative mortality by dru ...
Hypertension in patients with Type 2 Diabetes Mellitus – why are we
... • Current evidence suggests that in the management of patients with type 2 diabetes mellitus achieving target BP <= 130/80 may be the most important therapeutic goal • Internationally, there is very poor compliance with BP targets in diabetics - partly due to genuine difficulty achieving the BP targ ...
... • Current evidence suggests that in the management of patients with type 2 diabetes mellitus achieving target BP <= 130/80 may be the most important therapeutic goal • Internationally, there is very poor compliance with BP targets in diabetics - partly due to genuine difficulty achieving the BP targ ...
D
... addition, as in non-diabetic subjects, the protective effects of perindopril were independent of blood pressure at baseline, and independent of the blood pressure reduction achieved by the drug, suggesting that perindopril may exert its protective effect via other mechanisms e.g. accumulation of bra ...
... addition, as in non-diabetic subjects, the protective effects of perindopril were independent of blood pressure at baseline, and independent of the blood pressure reduction achieved by the drug, suggesting that perindopril may exert its protective effect via other mechanisms e.g. accumulation of bra ...
Elevated Liver Function Tests in Type 2 Diabetes
... steatosis. In the patients without clear etiology of liver disease, the prevalence rate of steatosis and steatohepatitis was 50.6 and 32%, respectively. In a similar study, 354 patients, both with and without diabetes, underwent liver biopsy to investigate abnormal LFTs. When patients with clinical ...
... steatosis. In the patients without clear etiology of liver disease, the prevalence rate of steatosis and steatohepatitis was 50.6 and 32%, respectively. In a similar study, 354 patients, both with and without diabetes, underwent liver biopsy to investigate abnormal LFTs. When patients with clinical ...
Elevated Liver Function Tests in Type 2 Diabetes
... steatosis. In the patients without clear etiology of liver disease, the prevalence rate of steatosis and steatohepatitis was 50.6 and 32%, respectively. In a similar study, 354 patients, both with and without diabetes, underwent liver biopsy to investigate abnormal LFTs. When patients with clinical ...
... steatosis. In the patients without clear etiology of liver disease, the prevalence rate of steatosis and steatohepatitis was 50.6 and 32%, respectively. In a similar study, 354 patients, both with and without diabetes, underwent liver biopsy to investigate abnormal LFTs. When patients with clinical ...
CARDIOMETABOLIC PROFILE IN DRIED BLOOD SPOT
... Which Biomarkers are Included in the CardioMetabolic Profile? High Sensitivity C-Reactive Protein (hs-CRP) C-reactive protein (CRP) is an established marker of inflammation and has recently been suggested to be an important contributor to pro-inflammatory and pro-thrombotic elements of CVD risk. Ext ...
... Which Biomarkers are Included in the CardioMetabolic Profile? High Sensitivity C-Reactive Protein (hs-CRP) C-reactive protein (CRP) is an established marker of inflammation and has recently been suggested to be an important contributor to pro-inflammatory and pro-thrombotic elements of CVD risk. Ext ...
Diabetes and Renal Disease
... Frequent sepsis Silent ischaemia 2-3 x death rate vs non-DM patients ...
... Frequent sepsis Silent ischaemia 2-3 x death rate vs non-DM patients ...
ALLHAT and its implications in the diabetic population
... For all participants the goal BP was less than 140/90 mmHg. If the BP goal was not achieved using first-step, blinded therapy, treating physicians had the choice of openlabel S = step 2 medications (reserpine, clonidine or atenolol). The study had a large enough sample size to capture treatment diff ...
... For all participants the goal BP was less than 140/90 mmHg. If the BP goal was not achieved using first-step, blinded therapy, treating physicians had the choice of openlabel S = step 2 medications (reserpine, clonidine or atenolol). The study had a large enough sample size to capture treatment diff ...
ROLE OF PIOGLITAZONE ON PROGRESSION OF ATHEROSCLEROSIS IN PREDIABETES: A... REVIEW Review Article
... Prediabetes is an intermediate stage between normal glycemia and clinical diabetes. Individual with prediabetes condition are more prone to diabetes and its associated cardiovascular disorder. Early intervention of prediabetes subjects reduces the development of diabetes and cardiovascular disease. ...
... Prediabetes is an intermediate stage between normal glycemia and clinical diabetes. Individual with prediabetes condition are more prone to diabetes and its associated cardiovascular disorder. Early intervention of prediabetes subjects reduces the development of diabetes and cardiovascular disease. ...
Diabetes: controversies and news
... versus 1.0 percent) and more weight gain (mean 3.5 versus 0.4 kg at three years) than the standard group (median A1C 7.5 percent). ...
... versus 1.0 percent) and more weight gain (mean 3.5 versus 0.4 kg at three years) than the standard group (median A1C 7.5 percent). ...
RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES
... thickness of head, body and tail appear to be reduced in diabetics but this reduction varied. This is seen maximum in insulin dependent diabetes mellitus patients, moderate in non insulin dependent and insulin treated patients. The reduction of size involved the body of the pancreas more than any ot ...
... thickness of head, body and tail appear to be reduced in diabetics but this reduction varied. This is seen maximum in insulin dependent diabetes mellitus patients, moderate in non insulin dependent and insulin treated patients. The reduction of size involved the body of the pancreas more than any ot ...
Highlights PACD18 - Pan Arab Conference on Diabetes
... 6Beisswenger 29:6S95-103; 7Leverve XM 29:6S88-94; 8Mamputu JC 29:6S71-6; ...
... 6Beisswenger 29:6S95-103; 7Leverve XM 29:6S88-94; 8Mamputu JC 29:6S71-6; ...
Oxidative Stress and Paraoxonase Status for Coronary Artery
... significantly higher in NIDDM patients as compared to controls. Pias et al [14], shown it to be important risk factor with a dose related risk in Indian patients. Smoking cessation may thus prove to be one of the most cost effective approaches in both primary and secondary prevention. Like other stu ...
... significantly higher in NIDDM patients as compared to controls. Pias et al [14], shown it to be important risk factor with a dose related risk in Indian patients. Smoking cessation may thus prove to be one of the most cost effective approaches in both primary and secondary prevention. Like other stu ...
Don`t Ignore Diabetes
... People with diabetes need to be aggressively treated for cardiovascular (heart and blood vessel) disease. This is the conclusion from a Canadian study published this month in the Lancet medical journal. Almost 6 million people without diabetes and nearly 400,000 people with diabetes were included in ...
... People with diabetes need to be aggressively treated for cardiovascular (heart and blood vessel) disease. This is the conclusion from a Canadian study published this month in the Lancet medical journal. Almost 6 million people without diabetes and nearly 400,000 people with diabetes were included in ...
Diabetes Guidelines An Approach to Diagnosis and Treatment A
... LDL-C<100 mg/dl/Non-HDL-C <130 mg/dl in those with no additional CVD or risk factors LDL-C <70 mg/dl/non-HDL-C<100 mg/dl for those with established CVD, 2 additional risk factors Statins are treatment of choice for those not reaching goal with lifestyle modifications Level A evidence Measured annual ...
... LDL-C<100 mg/dl/Non-HDL-C <130 mg/dl in those with no additional CVD or risk factors LDL-C <70 mg/dl/non-HDL-C<100 mg/dl for those with established CVD, 2 additional risk factors Statins are treatment of choice for those not reaching goal with lifestyle modifications Level A evidence Measured annual ...
comments and responses - Diabetes Care
... the ranking of the A1C target of ⬍7.0% as level-A evidence is based on a small number of patients in a single randomized study and on observational data (e.g., achieved glycemic levels) from most other randomized studies, this degree of confidence seems excessive to us. However, the ADVANCE study of ...
... the ranking of the A1C target of ⬍7.0% as level-A evidence is based on a small number of patients in a single randomized study and on observational data (e.g., achieved glycemic levels) from most other randomized studies, this degree of confidence seems excessive to us. However, the ADVANCE study of ...
Rosiglitazone
Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits.Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the U.S. From November 2011 until November 2013, the federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug.In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks. It was withdrawn from the market in the UK and India in 2010, and in New Zealand and South Africa in 2011.